Hashimoto's encephalopathy after interferon therapy for hepatitis C virus in adult liver transplant recipient accompanied by post-transplant lymphoproliferative disorder related to Epstein-Barr virus infection: Case report

Transplant Infectious Disease

Volumn 12, Issue 4, 2010, Pages 347-352

  Hori, T ^a,b   Oike, F ^a   Hata, K ^a   Nishikiori, M ^a   Ogura, Y ^a   Ogawa, K ^a   Takada, Y ^a   Egawa, H ^a   Nguyen, J H ^b   Uemoto, S ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b MAYO CLINIC   (United States)

Author keywords

Epstein Barr virus; Hashimoto's encephalopathy; hepatitis C virus; interferon; liver transplantation; post transplant lymphoproliferative disorder

Indexed keywords

ACICLOVIR; CYCLOSPORIN A; HYDROCORTISONE; METHYLPREDNISOLONE; PEGINTERFERON; PREDNISOLONE; RIBAVIRIN; STEROID; TACROLIMUS; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CONVULSION; DRUG PULSE THERAPY; ELECTROENCEPHALOGRAPHY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HASHIMOTO ENCEPHALOPATHY; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER GRAFT; LIVING DONOR; LYMPHOPROLIFERATIVE DISEASE; PANCYTOPENIA; PRIORITY JOURNAL; TUMOR LYSIS SYNDROME; UNCONSCIOUSNESS;

ANTIVIRAL AGENTS; BRAIN DISEASES; DRUG THERAPY, COMBINATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HASHIMOTO DISEASE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 77955955325     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00508.x     Document Type: Article

References (19)

1. Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005 5 (9) : 2222 2228.
2. Mocellin R, Walterfang M, Velakoulis D. Hashimoto's encephalopathy: epidemiology, pathogenesis and management. CNS Drugs 2007 21 (10) : 799 811.
3. Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006 63 (2) : 197 202.
4. Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol 2003 60 (2) : 164 171.
5. Deutsch M, Koskinas J, Tzannos K, et al. Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin. Ann Pharmacother 2005 39 (10) : 1745 1748.
6. Stevens RB, Wakefield CB, Alonso D, et al. Hashimoto's encephalopathy after intensive lymphocyte depletion with rabbit anti-thymocyte globulin in a renal transplant patient. Am J Transplant 2008 8 (1) : 245 249.
7. Sam CK, Brooks LA, Niedobitek G, et al. Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. Int J Cancer 1993 53 (6) : 957 962.
8. Yamamoto T, Tsuji K, Suzuki D, et al. A novel, noninvasive diagnostic probe for hydroa vacciniforme and related disorders: detection of latency-associated Epstein-Barr virus transcripts in the crusts. J Microbiol Methods 2007 68 (2) : 403 437.
9. Yuki N, Matsumoto S, Tadokoro K, et al. Significance of liver negative-strand HCV RNA quantitation in chronic hepatitis C. J Hepatol 2006 44 (2) : 302 309.
10. Gu C, Zheng C, Shi L, et al. Plus- and minus-stranded foot-and-mouth disease virus RNA quantified simultaneously using a novel real-time RT-PCR. Virus Genes 2007 34 (3) : 289 298.
11. Takada Y, Haga H, Ito T, et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation 2006 81 (3) : 350 354.
12. Hori T, Kuribayashi K, Uemoto S, et al. Alloantigen-specific prolongation of allograft survival in recipient mice treated by alloantigen immunization following ultraviolet-B irradiation. Transpl Immunol 2008 19 (1) : 45 54.
13. Yagi S, Iida T, Taniguchi K, et al. Impact of portal venous pressure on regeneration and graft damage after living-donor liver transplantation. Liver Transpl 2005 11 (1) : 68 75.
14. Machida K, Tsukiyama-Kohara K, Sekiguch S, et al. Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins. Gastroenterology 2009 137 (1) : 285 296.
15. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999 94 (7) : 2208 2216.
16. Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999 62 (4) : 247 250.
17. Sobel DO, Ahvazi B, Amjad F, Mitnaul L, Pontzer C. Interferon-tau inhibits the development of diabetes in NOD mice. Autoimmunity 2008 41 (7) : 543 553.
18. Sprengers D, Stoop JN, Binda RS, et al. Induction of regulatory T-cells and interleukin-10-producing cells in non-responders to pegylated interferon-alpha therapy for chronic hepatitis B. Antivir Ther 2007 12 (7) : 1087 1096.
19. Li J, Qian CN, Zeng YX. regulatory T cells and EBV associated malignancies. Int Immunopharmacol 2009 9 (5) : 590 592.